CONDENSED UNAUDITED INTERIM STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (13,401,734)	$ (7,943,593)
Adjustment to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation	13,680	13,680
Stock-based compensation, including the issuance of restricted stock	2,115,795	1,097,984
Acquired in-process research and development assets		25,000
Changes in operating assets and liabilities:
Collaboration receivable		7,500,000
Prepaids and other current assets	2,298,347	(2,241,700)
Accounts payable	(656,784)	716,067
Accrued expenses	1,450,625	(1,883,022)
Deferred collaboration revenue	(421,500)	297,891
Net cash used in operating activities	(8,601,571)	(2,417,693)
Cash flows from investing activities:
Purchase of in-process research and development assets		(25,000)
Net cash used in investing activities		(25,000)
Cash flows from financing activities:
Proceeds from subscription receivable		11,250
Proceeds from sale of common stock		5,000,000
Payment of financing costs related to the 2023 Private Placement		(131,918)
Proceeds from the exercise of stock options	19,137	1,975
Proceeds from the exercise of warrants		1,509,707
Net cash provided by financing activities	19,137	6,391,014
Net (decrease) increase in cash and cash equivalents	(8,582,434)	3,948,321
Cash and cash equivalents as of beginning of the period	38,339,762	32,626,768
Cash and cash equivalents as of end of the period	$ 29,757,328	36,575,089
Supplemental disclosures of non-cash financing activities:
Financing costs related to the sale of common stock in accounts payable		$ 56,332